Dallas—Physicians may soon have another option available for reducing stroke risk in patients with atrial fibrillation.
At the Scientific Sessions of the American Heart Association (AHA) held here in November, attendees heard promising results regarding edoxaban, an oral factor Xa inhibitor that was found to be noninferior to well-managed warfarin (median time in the therapeutic range, 68.4%) for the prevention of stroke or systemic embolism. Edoxaban use was also associated with lower rates of bleeding and death from cardiovascular causes when compared with warfarin, the vitamin K antagonist and most widely prescribed anticoagulant medicine (Giugliano RP et al. N Eng J Med. doi:10.1056/NEJMoa1310907 [published online November 19, 2013]).
Graphic Jump Location
New oral anticoagulant treatments of atrial fibrillation reduced hemorrhagic strokes by about 50% compared with warfarin in a recent study.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.